Giuseppe Lamberti
@GLambertiMD
Followers
284
Following
824
Statuses
125
Clin Res Fellow @DFCI | Fixed-term researcher in Med Onc @unibo | Research interests: neuroendocrine tumors, SCLC, methods in clinical cancer research
Joined February 2019
💫 Just out our collaborative work suggesting that adding temozolomide to capecitabine (CAPTEM) 💊 may improve outcomes 📈 in patients with atypical carcinoids 🫁 🤩 Thanks to all the Authors (and friends) for their invaluable efforts @SpringerNature
0
0
1
RT @OncoAlert: In metastatic non-small cell lung cancer treated w/ First-line pembrolizumab 🧪and cemiplimab ✅ PD-L1 expression ≥9⃣0⃣%, ha…
0
10
0
RT @yekeduz_emre: 🔥 A must-read review pertaining to "tumor mutational burden" , which is a predictor of response to PD(L)-1 inhibition 🎯…
0
18
0
RT @DiseasePrimers: Our NEW Primer on Gastric neuroendocrine neoplasms is live today! By @GLambertiMD, Panzuto, Pavel, O’Toole, Ambrosini,…
0
3
0
RT @QuantumOnc: A pleasure meeting with 2 brilliant minds @aiom @DanaFarber group and such wonderful hosts. Grazie ! See you soon. #Aiom #A…
0
3
0
I hope this finding will pave the way to new treatment options and outcome improvements for all patients. Thanks to the incredible team work with @BiagioRicciutMD and the terrific mentorship by @DrMarkAwad!
Now out in @JCO_ASCO, led by the outstanding @BiagioRicciutMD and @GLambertiMD, is our group's effort to elucidate mechanisms of resistance to PD-1 #immunotherapy in #lungcancer
0
1
9
RT @DanaFarberNews: In a new study published in @JCO_ASCO, @DrMarkAwad, @BiagioRicciutiMD, and @GLambertiMD @DanaFarber have uncovered mech…
0
15
0
0
0
2
RT @BiagioRicciutMD: Thanks @CCR_AACR for featuring our work on the clinico-genomic landscape of #ATM mutations in #NSCLC on this month’s c��
0
10
0
RT @TalalZarif1: Taking a moment to appreciate all the amazing people behind this study out today @JCO_ASCO that has been in the works for…
0
49
0
RT @caliraf: Just published! Great collaboration with Prof @LaurenByersMD and Prof Andrea Ardizzoni's Teams, led by Dr @lauramolinerj Nov…
0
14
0
RT @lauramolinerj: What to do in SCLC after progression to 1st line? 💊 Our review focus in current and - hopefully 🤞- future options for…
0
5
0
@GRecondoMD @JCOPO_ASCO @OncoAlert @DrMarkAwad Thank you, my friend! And thanks to Mark’s mentorship!
0
0
1
RT @JCOPO_ASCO: In this retrospective series, @GLambertiMD et al reported on intracranial activity of sotorasib in pts w/ #KRAS G12C mut #N…
0
9
0
RT @DrMarkAwad: Excited to be heading to Santa Monica for #TTLC with our research group! Very thankful to work with such kind and talented…
0
7
0
RT @ACortelliniMD: Comprehensive analysis ~1300pts treated w CT-IO on @JTOonline🎯Another piece led by the stellar @DanaFarber lung team @al…
0
12
0
RT @BiagioMd: KEAP1 mutations (mut) are heterogeneous in lung adenocarcinoma (LUAD). In this study out in @Annals_Oncology we found that cl…
0
36
0